Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy (original) (raw)

Abstract

sparkles

AI

This study investigates the dysregulation of GABAergic and glutamatergic neurotransmitter systems in individuals at ultra-high risk (UHR) for psychosis using proton magnetic resonance spectroscopy (1H MRS). Results indicate significant elevations of GABA and Glx levels within the medial prefrontal cortex (MPFC) of the UHR group, contrasting with control subjects, and reveal strong correlations between these neurotransmitters across different brain regions. The findings highlight potential biomarkers for the progression to psychosis and underscore the importance of targeting GABA and glutamate systems in treatment development for at-risk populations.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (57)

  1. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran G, Rylett RJ, Neufeld RW (1997) Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychia- try 54:959-965.
  2. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, Jiang ZI, Benneyworth MA, Froimowitz MP, Lange N, Snyder SH, Bergeron R, Coyle JT (2009) Targeted disruption of serine race- mase affects glutamatergic neurotransmission and behavior. Mol Psychiatry 14:719-727.
  3. Benes FM (1995) Altered glutamatergic and GABAergic mecha- nisms in the cingulate cortex of the schizophrenic brain. Arch Gen Psychiatry 52:1015-1018.
  4. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriello J (2010) 1H-MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry 15:629-636.
  5. Bustillo JR, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S (2011) Glutamate as a marker of cognitive function in schizophrenia: a proton spectro- scopic imaging study at 4 Tesla. Biol Psychiatry 69:19-27.
  6. Carlsson M, Carlsson A (1989) The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine- depleted mice. J Neural Transm 75:221-226.
  7. Carlsson M, Carlsson A (1990) Interactions between glutamater- gic and monoaminergic systems within the basal ganglia- -implications for schizophrenia and Parkinson's disease. Trends Neurosci 13:272-276.
  8. Dandash O, Fornito A, Lee J, Keefe RS, Chee MW, Adcock RA, Pan- telis C, Wood SJ, Harrison BJ (2014) Altered striatal functional connectivity in subjects with an at-risk mental state for psy- chosis. Schizophr Bull 40:904-913.
  9. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, Graff-Guerrero A (2011) Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 36:1781-1791.
  10. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A (2013a) Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol 16:471-475.
  11. de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Stephano S, Favila R, Diaz-Galvis L, Alvarado-Alanis P, Ramirez-Bermudez J, Graff-Guerrero A (2013b) Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 70:1057-1066.
  12. First MB, Spitzer RL, Williams JB, Gibbon M (1997) Structured Clinical Interview for DSM-IV Disorders (SCID). Washington, DC: American Psychiatric Association.
  13. Friston KJ, Ashburner J, Frith CD, Poline JB, Heather JD, Frack- owiak RSJ (1995) Spatial registration and normalization of images. Human Brain Mapping 3:165-189.
  14. Fusar-Poli P, Nelson B, Valmaggia L, Yung AR, McGuire PK (2014) Comorbid depressive and anxiety disorders in 509 individu- als with an at-risk mental state: impact on psychopathology and transition to psychosis. Schizophr Bull 40:120-131.
  15. Fusar-Poli P, Bonoldi I, Yung AR, Borgwardt S, Kempton MJ, Val- maggia L, Barale F, Caverzasi E, McGuire P (2012) Predicting psychosis: meta-analysis of transition outcomes in individu- als at high clinical risk. Arch Gen Psychiatry 69:220-229.
  16. Geramita M, van der Veen JW, Barnett AS, Savostyanova AA, Shen J, Weinberger DR, Marenco S (2011) Reproducibility of prefrontal gamma-aminobutyric acid measurements with J-edited spectroscopy. NMR Biomed 24:1089-1098.
  17. Goto N, Yoshimura R, Moriya J, Kakeda S, Ueda N, Ikenouchi-Sug- ita A, Umene-Nakano W, Hayashi K, Oonari N, Korogi Y, Naka- mura J (2009) Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr Res 112:192-193.
  18. Goto N, Yoshimura R, Kakeda S, Nishimura J, Moriya J, Hayashi K, Katsuki A, Hori H, Umene-Nakano W, Ikenouchi-Sugita A, Korogi Y, Nakamura J (2012) Six-month treatment with de la Fuente-Sandoval et al. | 9 atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizo- phrenia. Neuropsychiatr Dis Treat 8:119-122.
  19. Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, Volk DW, Mirnics K, Lewis DA (2008) Alterations in GABA- related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 13:147-161.
  20. Jinno S, Kosaka T (2004) Parvalbumin is expressed in glutamater- gic and GABAergic corticostriatal pathway in mice. J Comp Neurol 477:188-201.
  21. Kegeles LS, Mao X, Dyke J, Gonzales R, Soones T, Shungu DC (2006) Test-retest reliability of dorsolateral prefrontal corti- cal GABA measurement using an 8-channel phased-array head coil with the J-editing technique at 3T. Proc Intl Soc Mag Reson Med 14:489.
  22. Kegeles LS, Mao X, Stanford AD, Girgis R, Ojeil N, Xu X, Gil R, Slifstein M, Abi-Dargham A, Lisanby SH, Shungu DC (2012) Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry 69:449-459.
  23. Kegeles LS, Mao X, Ojeil N, Massuda R, Pedrini M, Chen C-M, Slifstein M, Abi-Dargham A, Milak M, C. R, Shungu DC (2013) J-editing/MEGA-PRESS Time-course Study of the Neurochem- ical Effects of Ketamine Administration in Healthy Humans. Proc Intl Soc Mag Reson Med 21:1206.
  24. Kraguljac NV, White DM, Reid MA, Lahti AC (2013) Increased hip- pocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 70:1294-1302.
  25. Kraguljac NV, Reid MA, White DM, den Hollander J, Lahti AC (2012) Regional decoupling of N-acetyl-aspartate and gluta- mate in schizophrenia. Neuropsychopharmacology 37:2635- 2642.
  26. Lewis DA, Hashimoto T, Volk DW (2005) Cortical inhibitory neu- rons and schizophrenia. Nat Rev Neurosci 6:312-324.
  27. Lorrain DS, Baccei CS, Bristow LJ, Anderson JJ, Varney MA (2003) Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modula- tion by a group II selective metabotropic glutamate receptor agonist LY379268. Neuroscience 117:697-706.
  28. Markwardt CB. Non-linear Least-squares Fitting in IDL with MPFIT. Paper presented at: Proceedings of Astronomical Data Analysis Software and Systems XVIII 2008, 2009; San Fran- cisco, CA.
  29. Milak MS, Proper CJ, Mulhern ST, Parter AL, Kegeles LS, Ogden RT, Mao X, Rodriguez CI, Oquendo MA, Suckow RF, Cooper TB, Keilp JG, Shungu DC, Mann JJ (2015) A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neuro- transmitter response to ketamine treatment of major depres- sive disorder. Mol Psychiatry doi: 10.1038/mp.2015.83.
  30. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Cannon T, Ventura J, McFarlane W, Perkins DO, Pearlson GD, Woods SW (2003) Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symp- toms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 29:703-715.
  31. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminer- gic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2927.
  32. Natsubori T, Inoue H, Abe O, Takano Y, Iwashiro N, Aoki Y, Koike S, Yahata N, Katsura M, Gonoi W, Sasaki H, Takao H, Kasai K, Yamasue H (2014) Reduced Frontal Glutamate + Glutamine and N-Acetylaspartate Levels in Patients With Chronic Schiz- ophrenia but not in Those at Clinical High Risk for Psychosis or With First-Episode Schizophrenia. Schizophr Bull 40:1128- 1139.
  33. Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
  34. Ongur D, Prescot AP, McCarthy J, Cohen BM, Renshaw PF (2010) Elevated gamma-aminobutyric acid levels in chronic schizo- phrenia. Biol Psychiatry 68:667-670.
  35. Ota M, Ishikawa M, Sato N, Hori H, Sasayama D, Hattori K, Terai- shi T, Nakata Y, Kunugi H (2012) Glutamatergic changes in the cerebral white matter associated with schizophrenic exacer- bation. Acta Psychiatr Scand 126:72-78.
  36. Puhl MD, Mintzopoulos D, Jensen JE, Gillis TE, Konopaske GT, Kaufman MJ, Coyle JT (2014) In vivo magnetic resonance studies reveal neuroanatomical and neurochemical abnor- malities in the serine racemase knockout mouse model of schizophrenia. Neurobiol Dis 73C:269-274.
  37. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, Knowlton RC, den Hollander JA, Lahti AC (2010) Assess- ments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry 68:625-633.
  38. Rothman DL, Petroff OA, Behar KL, Mattson RH (1993) Local- ized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. Proc Natl Acad Sci U S A 90:5662-5666.
  39. Rowland LM, Kontson K, West J, Edden RA, Zhu H, Wijtenburg SA, Holcomb HH, Barker PB (2013) In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull 39:1096-1104.
  40. Sailasuta N, LeRoux P, Hurd R, Wang P, Sachs N, Ketter T (2001) Detection of cerebral gamma-aminobutyric acid (GABA) in bipolar disorder patients and healthy volunteers at 3 T. Proc Intl Soc Magn Reson Med 9:1011.
  41. Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, Lieberman JA, Moore H, Small SA (2013) Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocam- pal dysfunction and implicates glutamate as a driver. Neuron 78:81-93.
  42. Shungu DC (2013) Demystifying the "Glx" peak that co-edits with GABA by J-editing. In: Proceedings of the 2nd Cardiff Interna- tional Symposium on MRS of GABA Cardiff, Wales, UK.
  43. Shungu DC, Mao X, Gu M, Milak MS, Weiduschat N, Mayer D, Spielman D, Mann JJ, Kegeles LS (2013) 'Glx' measured by J-editing/MEGA-PRESS is primarily 'pure' glutamate…or is it? Proc Int Soc Magn Reson Med 21:3985.
  44. Singh F, Mirzakhanian H, Fusar-Poli P, de la Fuente-Sandoval C, Cadenhead KS (2012) Ethical implications for clinical practice and future research in "at risk" individuals. Curr Pharm Des 18:606-612.
  45. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, Krystal JH, Nutt D, Barker GJ (2012) Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ket- amine-induced psychopathology. Mol Psychiatry 17:664-665.
  46. Stone JM, Day F, Tsagaraki H, Valli I, McLean MA, Lythgoe DJ, O'Gorman RL, Barker GJ, McGuire PK, Oasis (2009) Glutamate dysfunction in people with prodromal symptoms of psy- chosis: relationship to gray matter volume. Biol Psychiatry 66:533-539.
  47. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, O'Gorman RL, McLean MA, Barker GJ, McGuire P (2010) Altered relationship between hippocampal glutamate levels and stri- atal dopamine function in subjects at ultra high risk of psy- chosis. Biol Psychiatry 68:599-602.
  48. Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, Keshavan MS (2013) Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res 148:59-66.
  49. Tayoshi S, Nakataki M, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, Ueno S, Harada M, Ohmori T (2010) GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study. Schizophr Res 117:83-91.
  50. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ (2003) Glu- tamate and glutamine in the anterior cingulate and thala- mus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 160:2231-2233.
  51. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neu- feld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al- Semaan Y, Williamson PC (2002) Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 159:1944-1946.
  52. Tu PC, Hsieh JC, Li CT, Bai YM, Su TP (2012) Cortico-striatal discon- nection within the cingulo-opercular network in schizophre- nia revealed by intrinsic functional connectivity analysis: a resting fMRI study. Neuroimage 59:238-247.
  53. Wechsler D (1997) Wechsler Adult Intelligence Scale III. San Antonio, TX: The Psychological Corporation.
  54. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, Charlson FJ, Norman RE, Flaxman AD, Johns N, Burstein R, Murray CJ, Vos T (2013) Global burden of disease attributable to mental and substance use disorders: find- ings from the Global Burden of Disease Study 2010. Lancet 382:1575-1586.
  55. Wood SJ, Kennedy D, Phillips LJ, Seal ML, Yucel M, Nelson B, Yung AR, Jackson G, McGorry PD, Velakoulis D, Pantelis C (2010) Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuro- image 52:62-68.
  56. Yoon JH, Maddock RJ, Rokem A, Silver MA, Minzenberg MJ, Rag- land JD, Carter CS (2010) GABA concentration is reduced in visual cortex in schizophrenia and correlates with orien- tation-specific surround suppression. J Neurosci 30:3777- 3781.
  57. Yung A, Phillips L, McGorry P (1998) Prediction of psychosis, a step towards indicated prevention of schizophrenia. Br J Psy- chiatry 172:14-20.